Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (102)	9/11/2002 1:03:25 PM
From: tuck	Read Replies (1) \| Respond to of 126

Corvas solidly in roach motel land. At some point in the remaining months of this year, it is supposed to initiate PII for rNAPc2. Given the bottoming going on, that may pop the stock, but then I'd be getting out again, if I was in. Not much to drive it after that. Presenting in Germany this week: >> 16th International Congress on Fibrinolysis and Proteolysis in conjunction with the 17th International Fibrinogen Workshop September 08-13, 2002, Munich, Germany -------------------------------------------------------------------------------- S39 - Discovery and characterization of novel cancer-associated type II transmembrane serine proteases Madison E. L Corvas International, San Diego, CA, USA We have cloned a large number of novel, human, cancer-associated type II serine proteases, demonstrating that this interesting, emerging subfamily of serine proteases is significantly larger and more diverse than is currently appreciated. We have expressed and characterized many of these novel proteases, including the solution of high resolution X-ray crystal structures of the corresponding protease domains. In addition, we have established screening assays for many of these novel cancer-associated proteases and isolated small molecule or monoclonal antibody inhibitors for several of these enzymes. We have also designed innovative prodrugs that are activated by selected cancer-associated serine proteases. We have observed inhibition of primary tumor growth in xenograft models following administration of potent, selective small molecule inhibitors, neutralizing monoclonal antibodies, or protease-activated prodrugs targeted to specific, tumor-associated serine proteases.<< I don't follow Corvas very closely, at all, but there isn't anything new here, is there? Cheers, Tuck